Their goal is to catalyze more research across Europe to improve the understanding of psychedelic-assisted treatments. They also seek to inform and engage with mental health stakeholders through education and training efforts.
Norrsken Mind is a continuation of Osmond Foundation, which funded the first Swedish modern clinical trial using psilocybin-assisted therapy to treat depression at Karolinska Institutet.
As a player in the Health Care industry, Norrsken Mind's unique focus on psychedelic research positions it at the forefront of a growing field with the potential for significant impact on mental health care.
